Compartmental models for apical efflux by p-glycoprotein: Part 2 - A theoretical study on transporter kinetic parameters

Pharmaceutical Research

Volumn 31, Issue 2, 2014, Pages 335-346

  Korzekwa, Ken ^a   Nagar, Swati ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

compartmental models; intracellular concentrations; kinetics; P glycoprotein; transporters

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; QUINIDINE; VERAPAMIL; VINBLASTINE;

APICAL MEMBRANE; ARTICLE; COMPARTMENT MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MICHAELIS MENTEN KINETICS; PERMEABILITY BARRIER; PRIORITY JOURNAL; THEORETICAL STUDY;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; DOGS; KINETICS; MADIN DARBY CANINE KIDNEY CELLS; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PERMEABILITY; PHARMACEUTICAL PREPARATIONS;

EID: 84896731919     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1163-8     Document Type: Article

References (24)

1. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36.
2. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H et al. Best practices in determination of transporter kinetic parameters and translational models for human transporter-mediated pharmacokinetics and drug interactions. Clin Pharmacol Ther. 2013; In Press.
3. Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. FDA Guidance for Industry: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ default.htm.
4. Guideline on the Investigation of Drug Interactions. EMA Guidline www.ema.europa.eu
5. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y et al. Intracellular drug concentrations and transporters: measurement, modeling and implications in the liver. Clin Pharmacol Ther. 2013; In Press.
6. Korjamo T, Kemiläinen H, Heikkinen AT, Mönkkönen J. Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates. Drug Metab Dispos. 2007;35(9):1574-9.
7. Shirasaka Y, Masaoka Y, Kataoka M, Sakuma S, Yamashita S. Scaling of in vitro membrane permeability to predict P-glycoprotein-mediated drug absorption in vivo. Drug Metab Dispos. 2008;36(5):916-22.
8. Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, et al. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res. 2010;27(3):442-6.
9. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652-62.
10. Ménochet K, Kenworthy KE, Houston JB, Galetin A. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther. 2012;341(1):2-15.
11. Acharya P, O'Connor MP, Polli JW, Ayrton A, Ellens H, Bentz J. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metab Dispos. 2008;36(2):452-60.
12. Pang KS, Maeng HJ, Fan J. Interplay of transporters and enzymes in drug and metabolite processing. Mol Pharm. 2009;6(6):1734-55.
13. Sun TM, Du JZ, Yan LF, Mao HQ, Wang J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomater Engl. 2008;29(32):4348-55.
14. Fan J, Maeng HJ, Pang KS. Interplay of transporters and enzymes in the Caco-2 cell monolayer: I. effect of altered apical secretion. Biopharm Drug Dispos. 2010;31(4):215-27.
15. Bentz J, Tran TT, Polli JW, Ayrton A, Ellens H. The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. Pharm Res. 2005;22(10):1667-77.
16. Kalvass JC, Pollack GM. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res. 2007;24(2):265-76.
17. Korzekwa KR, Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, Hidalgo IJ. Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab Dispos. 2012;40(5):865-76.
18. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos. 2010;38(2):215-22.
19. Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, et al. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos. 2011;39(3):353-62.
20. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet. 1995;29:607-49.
21. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Current opinion in genetics & development. Elsevier; 1996;6(5):610-617.
22. Hennessy M, Spiers JP. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res. 2007;55(1):1-15.
23. Jin MS, Oldham ML, Zhang Q, Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature. 2012;490(7421):566-9.
24. Nagar S, Korzekwa K. Commentary: nonspecific protein binding versus membrane partitioning: it is not just semantics. Drug Metab Dispos. 2012;40(9):1649-52.